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INTRODUCTION: Sagliker described craniofacial, skeletal, neurologic and soft tissue abnormalities in
patients with secondary hyperparathyroidism with end-stage chronic renal disease. This unique entity
has been attributed to delay in treatment of renal insufﬁciency. As of 2012 sixty cases have been reported.
The aim of the study is to report this entity in ﬁve patients and to propose this condition as an indication
for parathyroidectomy.
METHODS: We report ﬁve patients. All patients had chronic renal failure (CRF) and secondary hyper-
parathyroidism that fulﬁlled the criteria for Sagliker syndrome and underwent parathyroid surgery. We
collected detailed information, including clinical history, laboratory data, and old/current photographs
for comparison.
RESULTS: The ﬁve patients, four women and one man mean age 21 years, had severe secondary hyper-
parathyroidism (mean serum preoperative PTH=3779.6pg/ml, mean preoperative Ca2+ = 8.83mg/dl and
P3– =5.66mg/dl); maxillary and mandibular bone changes; teeth/dental abnormalities; and soft and
benign tumors in the mouth. Three had severe uglifying facial appearance. All patients underwent total
parathyroidectomywithoutpostoperative complications.After surgerymeanserumPTHwas17.16pg/ml
(p=0.006), P3− =3.38mg/dl (p=0.0068) and Ca2+ = 6.97mg/dl (p=0.345). At surgery, average height was
149.8 cm, a mean of 6 cm (p=0.003) less than at the beginning of CRF. Preoperative Beck Depression
Inventory test mean score was 37 (severe depression); 6 months after surgery mean score was 15.8
(mild mood disturbance)(p=0.0001). Clinical follow-up was satisfactory with a mean follow up time of
14 months.
CONCLUSION: We consider that Sagliker syndrome should be added to current surgical indications for
parathyroidectomy.
© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Sagliker syndrome (SS) was described by Sagliker et al. in 2004.
Patients with chronic renal failure (CRF) have elevated levels of
serum phosphorus (P3−), parathyroid hormone (PTH) and alkaline
phosphatase with low levels of calcium (Ca2+). All these changes
occur as a result of renal function decline with a drop of 1,25-
dihydroxyvitamin D3 [1,25-(OH) 2 D3] levels and hypocalcemia
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secondary to impaired intestinal and renal Ca2+ absorption. PTH
secretion, regulated by serum Ca2+ levels, rises in response to
hypocalcemia. In early stages of CRF elevated circulating PTH lev-
els enhance P3− excretion and may result in decreased serum P3−
levels. In advanced stages of CRF, P3− excretion becomes impaired,
and hyperphosphatemia suppresses 1a-hydroxylase activity fur-
ther decreasing 1,25-(OH) 2D3production anddirectly stimulating
PTH release. A special subgroup of patients with CRF develop
multiple changes that include “uglifying” facial appearance, short
stature, extremely severe maxillary and mandibular changes, soft
tissues in themouth, teeth-dental abnormalities, ﬁnger tip changes
andseverepsychologicalproblems [1]. Theexpressionof all of these
changes has been described as Sagliker syndrome.
This unique entity has been attributed to delay in treatment of
renal insufﬁciency because of poverty and limited access to health
care [2].
http://dx.doi.org/10.1016/j.ijscr.2015.01.044
2210-2612/© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Left showing previously normal face (ﬁrst two patients), center and right showing current uglifying humanface appearances.
As of 2012, sixty cases had been reported in literature. The aim
of the study is to report this entity in ﬁve patients with end-stage
renal disease and to propose this condition as an indication for
parathyroidectomy.
2. Methods
In our study, we report ﬁve patients who were evaluated from
March of 2012 to October 2013.
All patients had CRF and secondary hyperparathyroidism
(sHPT), fulﬁlled the criteria for Sagliker syndrome, and underwent
parathyroid surgery. We collected detailed information, including
clinical history, physical exam and laboratory data.
We took face and body pictures and requested copies of pre-
vious pictures and family photo albums, which included pictures
of other family members. Informed consent was received from
patients and institutional review board approval was obtained. To
evaluate depression we performed Beck Depression Inventory test
[3] before and six months after surgery.
Descriptive statistics were used to analyze baseline char-
acteristics. Changes over time were analyzed with the use of
paired-samples Student’s t test. All statistical analyses were per-
formed with the use of STATA 12.
3. Results
Five patients, four females and onemalewith amedian age of 21
years, had chronic renal failure with a median interval of four years
between diagnosis of CRF and our evaluation. All presented with
severe secondaryhyperparathyroidism,withmean serumpreoper-
ative PTH=3779.6pg/ml, mean preoperative Ca2+ =8.83mg/dl and
P3– =5.66mg/dl.
Three patients had severe uglifying facial features; the dif-
ference in facial appearance in two cases is shown in current
photographs compared with those taken several years earlier (Fig.
1). The other two patients had mild uglifying facial features.
In all ﬁve cases teeth were irregularly shaped and located; three
of them had soft, large, tumor-like tissue accumulations particu-
larly in the upper side of the oral cavity (Fig. 2 ). All had difﬁculty
standing, but none had ﬁngertip changes, scapula deformity, or
hearing problems (Table 1 ). Average height at the beginning of
CRF was 155.8 cm.
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Fig. 2. (a) Showing maxillary and mandibular bone changes, dental malocclusion (b
and c) soft and benign tumors in the mouth.
Table 1
Clinical characteristics.
Age Sex Dental
abnormali-
ties
Mandibular
abnormali-
ties
Finger tips
abnormalities
Height
differences
(cm)
1 21 F Yes Yes No 10
2 27 F Yes Yes No 5
3 19 F Yes Yes No 5
4 21 F Yes Yes No 5
5 29 M Yes Yes No 5
21a 6 cmb (p=0.003)
a Median.
b Mean.
Table 2
Laboratory and test results.
Preoperative Postoperative P
PTH (pg/ml) 3779.6 17.16a 0.006
Ca+2(mg/dl) 8.83 6.97a 0.345
P−3 (mg/dl) 5.66 3.38a 0.0068
Beck test score 37 15.8b 0.0001
a After one week.
b After six months.
All patients underwent total parathyroidectomy without
thymectomy. Parathyroid glands were easily identiﬁed because of
their enlarged size and in each case the four glands were removed.
There were not postoperative complications. After surgery
mean serum PTH was 17.16pg/ml (p=0.006), P3− =3.38mg/dl
(p=0.0068) and Ca2+ =6.97mg/dl (p=0.345) (Table 2).
At surgery, average height was 149.8 cm, a decrease of 6 cm
(p=0.003) from the beginning of CRF (Fig. 3 ).
Fig. 3. Picture shows differences height between one patient and her mother (left
picture 12 years-old and right 21 years-old).
The Beck Depression Inventory test yielded a mean score of
37 (severe depression) preoperatively; 6 months after surgery the
mean score was 15.8 (mild mood disturbance); the difference was
statistically signiﬁcant (P=0.0001).
Preoperatively all patients were treated with supplements of
mean oral calcium (600mg/d), alfacalcidol (1–2g/d), iron sucrose
injection (200mg/week), erythropoietin injection (50UI/kg/week)
Two patient were treated with amlodipine (10mg/d), atenolol
(50mg/d), enalapril (20mg/d) and another patientwas given losar-
tan (50mg/d). Postoperatively all dosages remained the same
except for mean oral calcium which was increased to 1200mg/TID.
Clinical follow-up was satisfactory with a mean follow up time of
14 months.
4. Discussion
Sagliker syndrome is assumed to result from insufﬁcient treat-
ment of sHPT in early stages of CRF. This syndrome can be observed
in developing countries where people lack access to necessary
medical treatment and do not receive timely treatment for renal
insufﬁciency [4]. Our country, is an economically distressed, has
the disadvantages that could lead to the appearance of SS.
Our patients had CRF onset a median of 4 years prior to our
evaluation, but none of them reported having delayed treatment,
according to themedical history interview. Although these patients
are economically disadvantaged and have scarce resources, we
could not determine by interview that treatment (such as oral cal-
cium, alfacalcidol, erythropoietin injection and anti-hypertensive
medication) had been recommended but not received.
Patients were referred for parathyroidectomy for secondary
hyperparathyroidism. None had the possibility of a renal trans-
plant because they could not afford surgery and/or long-term
immunosuppression, so we made the decision to perform a total
parathyroidectomy without thymectomy. We consider that to per-
form a thymectomy augments the morbidity of these already frail
patients, specially considering that bydeﬁnitionpatientswith renal
failure have coagulation problems [5].
We chose total parathyroidectomy instead of subtotal parathy-
roidectomy because our goal is to avoid persistence and recurrence
ofdisease. The largest studypublishedbySchneider et al. [6] reports
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rates of 4.1% of persistence and 6.1% of recurrence with subtotal
parathyroidectomy with thymectomy compared to 0% persistence
and recurrence with total parathyroidectomy without thymec-
tomy. In our study we have a 0% persistence or recurrence of
hyperparathyroidism.
The other surgical alternative is total parathyroidectomy with
thymectomy with autotransplant. This option has 0.4% of persis-
tence and 5.4% of recurrence [6]. We did not consider that option
for the reasons given above.
All of the referred patients were clinically suited for surgery and
none had postoperative complications. Because we have followed
up these patients a mean of just 14 months, we are not surprised
not to have observed any changes in facial bone structure or other
bonedeformities;whether such changeswill develop later, as some
authors allege, is unknown.
This descriptive report respond to our effort to understand why
certain patients with CRF develop SS and what the optimal ther-
apy of SS is. Major limitations of this study are that our experience
is limited to ﬁve cases; we had no control group, either of CRF
patients without SS or SS patients given treatment other than
parathyroidectomy; and we gathered information only retrospec-
tively about the onset of CRF so we cannot determine cause-effect
relationships. It is still uncertain why a subgroup of patients with
sHPT develops SS. Genetic associations, and in particular, muta-
tions on the GNAS1 gene exons have been described and are seen
only in some of the SS patients [7]. In our patients we were not
able to performmolecular and genetic studies because of economic
restrictions.
Psychiatric problems have also been described. Depression and
anxiety disorder coexist with other SS symptoms [8]. Our inter-
views revealed that our patients had severe depression before
surgery, with improvement after surgery. Whether the improve-
mentwas a direct effect of parathyroidectomyor had another cause
could not be determined.
When pharmacological treatment of sHPT does not lead to
adequate regulation of parathyroid function, parathyroidectomy
should be performed and not delayed. We suggest that SS should
be considered an indication for parathyroidectomy.
In the meanwhile we need to continue gathering information to
determine why a subgroup of patients with sHPT develops SS.
5. Conclusion
Sagliker syndrome is a complicationof secondaryhyperparathy-
roidism in a subgroup of patients with CRF. We consider that
Sagliker Syndrome should be added to current surgical indications
for parathyroidectomy.
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